Grant: Alliance Grants
University of Toronto
$50,000.00
High-throughput serological assay for detection of cytokines/chemokines in COVID-19 patients_x000d_
FY 2020-21
Summary
COVID-19 is a novel viral illness, with a wide spectrum of clinical illness from asymptomatic to critical illness and death. The immune response to the virus may play an important role in the ultimate clinical outcome. It has been hypothesized that an inflammatory overactivity or "cytokine storm" may drive clinical deterioration in severe COVID-19. Patients with high levels of inflammation (or cytokines) have been found to have more severe disease and are more likely to die. It is therefore essential for us to unravel the inflammatory response to COVID-19, both to identify patients at-risk for deterioration and to define potential thresholds for initiation of therapies that target the immune response.
In order to do this, we need technologies to rapidly, efficiently, accurately measure cytokine levels. We aim to develop a technology, rooted in novel materials chemistry, to measure cytokine levels and as well antibodies against the SARS-CoV-2 antibody. This technology is based on the preparation of micrometre-sized plastic beads encoded with different metal atoms in which each encoded bead surface is coated with a capture biomolecule (antibody or antigen) to bind disease biomarkers from biological fluids collected from COVD-19 patients. In this way we can detecting 8 different cytokines in each patient sample. The technology can be expanded to detect 32 cytokines and antibodies in each sample. It also allows one to use secondary sample barcoding in order to analyze up to 20 patient samples in single test, where results can be acquired within a 1-hour timeframe. Upon development and deployment of this technology, we will use clinical samples from patients with COVID-19 to characterize the immune response and to conduct "serosurveillance" to identify and characterize patients who have been previously infected with COVID-19.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
555017-2020
Name nom
Winnik, Mitchell
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3751
Research subject group en
Polymer chemistry
Research subject group fr
Chimie des polymères
Research subject en
Polymer synthesis
Research subject fr
Synthèse des polymères
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
High-throughput serological assay for detection of cytokines/chemokines in COVID-19 patients_x000d_
Keyword
NSERC
Application summary
COVID-19 is a novel viral illness, with a wide spectrum of clinical illness from asymptomatic to critical illness and death. The immune response to the virus may play an important role in the ultimate clinical outcome. It has been hypothesized that an inflammatory overactivity or "cytokine storm" may drive clinical deterioration in severe COVID-19. Patients with high levels of inflammation (or cytokines) have been found to have more severe disease and are more likely to die. It is therefore essential for us to unravel the inflammatory response to COVID-19, both to identify patients at-risk for deterioration and to define potential thresholds for initiation of therapies that target the immune response.
In order to do this, we need technologies to rapidly, efficiently, accurately measure cytokine levels. We aim to develop a technology, rooted in novel materials chemistry, to measure cytokine levels and as well antibodies against the SARS-CoV-2 antibody. This technology is based on the preparation of micrometre-sized plastic beads encoded with different metal atoms in which each encoded bead surface is coated with a capture biomolecule (antibody or antigen) to bind disease biomarkers from biological fluids collected from COVD-19 patients. In this way we can detecting 8 different cytokines in each patient sample. The technology can be expanded to detect 32 cytokines and antibodies in each sample. It also allows one to use secondary sample barcoding in order to analyze up to 20 patient samples in single test, where results can be acquired within a 1-hour timeframe. Upon development and deployment of this technology, we will use clinical samples from patients with COVID-19 to characterize the immune response and to conduct "serosurveillance" to identify and characterize patients who have been previously infected with COVID-19.